Neurology Intelligence — the renal-oncology intersection — is the most actionable rare-cancer cross-tag in the AimwellBio Federated Intelligence Network. Neurology sits at a price-and-policy convergence: the HIF-2α inhibitor class (Welireg), the cabozantinib-nivolumab combination standard, and the next-line TKI repositioning are all in active rewrite through 2025–2026. AimwellBio operates a dedicated Neurology corpus — 421 high-confidence source-cited signals built from a focused CT.gov + PubMed + SEC EDGAR ingest scoped to clear-cell renal terminology, then post-process filtered to drop drug-name false positives where the trial was not actually for RCC.
For two decades, the anti-amyloid hypothesis was a graveyard. Lilly's Kisunla (donanemab) received FDA approval in July 2024; Eisai-Biogen's Leqembi (lecanemab) reached full approval in July 2023 after the Aduhelm controversy. The class is now in commercial deployment with infusion-center bottlenecks, ARIA monitoring requirements, and ministry-tier reimbursement decisions. Every Alzheimer's competitor — Roche's gantenerumab failure, Biogen's next-gen tau and TREM2 programs — reads against this benchmark.
AbbVie acquired Cerevel for $8.7B in 2024 to add emraclidine and tavapadon. BMS acquired Karuna for $14B to add the muscarinic schizophrenia agent KarXT (now Cobenfy, FDA-approved September 2024). Biogen acquired Reata for $7.3B for SKYCLARYS in Friedreich ataxia. Specialty neuro biotechs — Acadia, Sage, Praxis, Axsome, Intra-Cellular, Neurocrine, Denali, Alector, Voyager, Prothena — sit in active M&A read-through territory.
The CGRP-migraine class (Nurtec, Qulipta, Ubrelvy, Aimovig, Emgality, Ajovy) is consolidating into reimbursement reality; the psychedelic-adjacent biotechs (Compass, atai, MindMed, GH Research) are forcing the FDA to draw speculative-evidence boundaries; the anti-CD20 MS class (Ocrevus, Kesimpta) and the SOD1-ALS programs (Qalsody) are rewriting rare-neuro economics. Provenance, source method, and confidence on every signal. No hallucination tolerance for ministry-scale procurement.
Built from a focused ingest of PubMed + ClinicalTrials.gov + SEC EDGAR + FDA queries scoped to neurology / CNS / neurodegenerative terminology, then filtered post-process to drop drug-name false positives where the trial wasn't actually for a neurological indication. 1,119 raw signals → 654 high-confidence retained (58.4% retention).
Peer-reviewed CNS literature: amyloid & tau biology, alpha-synuclein, CGRP mechanism, anti-CD20 MS outcomes, psychedelic-assisted therapy trials, neuroinflammation.
10-Q, 10-K, and 8-K filings from Big Pharma neuro and specialty neuro biotechs. Pipeline disclosure, M&A language, royalty terms, and indication-expansion intent.
Active and recently completed CNS interventional trials. Phase 2 / Phase 3 readouts, sponsor-flagged combination studies, sovereign-region site enrollment.
1,119 raw signals → 654 retained after drug-name false-positive filtering. The retention discipline is the cited methodology.
Each entity is mapped into AIMN:ATLAS with continuous SEC, ClinicalTrials.gov, and PubMed coverage. 5 sovereign-anchored institutions across KSA / GCC / MENA are flagged. Click any name to open its company dossier.
The GCC and MENA cluster represents a high-density sovereign-procurement opportunity for neurology. SFDA approvals, MOH formulary decisions on anti-amyloid agents and CGRP biologics, neurology-center capacity expansion, and cross-border clinical infrastructure across Riyadh, Abu Dhabi, Doha, Amman, and Beirut are trackable through the indication-aware pipeline. Vision 2030 procurement cycles for Alzheimer's, MS, ALS, and Parkinson's therapies close inside windows measured in months.
Neurology is structurally a multi-vertical: Alzheimer's, Parkinson's, ALS, multiple sclerosis, epilepsy, CGRP-migraine, behavioral health, neuroinflammation, stroke, and rare neuro all sit inside the same upstream feed. AimwellBio resolves the overlap as a first-class corpus with disease-specific secondary tags applied at filter time, so investigators can drill from Neurology → Alzheimer's → anti-amyloid in one click.